SBC Medical Group Holdings Inc (SBC) stock intrinsic value fair value estimate & owner earnings analysis

SBC Medical Group Holdings runs the management, procurement and licensing side of the Shonan Beauty Clinic network, a 25-year-old Japanese aesthetic-medicine brand. At the end of 2025 it served 237 franchised treatment centers in Japan, 21 more in Singapore (through Aesthetic Healthcare Holdings, acquired November 2024) and one in Ho Chi Minh City, Vietnam. Because Japanese law requires clinics to be owned by physician-run medical corporations, SBC does not own the Japanese clinics. It earns fees from them: franchising (about $46M in 2025), procurement of equipment and supplies ($56M), management services ($30M), equipment rentals ($23M) and other items ($19M). Total 2025 revenue was $173.6M, down 15% from $205.4M. Two facts shape everything below. First, about 91% of revenue comes from the affiliated medical corporations, and three of them account for roughly two-thirds of sales. Second, the founder, Dr. Aikawa, holds about 85% of the voting power. The fee schedule those clinics pay is therefore set by related parties. That is exactly what happened on April 1, 2025, when service fees were reset by clinic size and performance: franchising revenue fell 25% and management-services revenue fell 44% (the latter also because a staffing-support license lapsed in January 2025). Those are the highest-margin lines, so gross profit fell 18% to $127.3M. How we measured earnings. We start from operating cash flow, strip out swings in working capital (including $14M of repayments of related-party notes and $12.7M of new equipment-lease receivables from the clinics in 2025, plus a $22M related-party retirement payment in 2023), deduct stock compensation (a one-time $13.0M merger award in 2024, none in 2025) and deduct maintenance capital spending. Rent paid on operating leases is treated as a real cost. Result: owner earnings of about $46.6M (2023), $48.2M (2024) and $44.9M (2025), or $0.49, $0.50 and $0.44 per share. Cash interest is negligible. We anchor on 2025 (about $45M, $0.44 per share) rather than the 2023-2024 median, because the April 2025 fee reset is a lasting change to the business and 2024 also carried the one-time stock award. Only three years of operating history exist in the filings. Growth reconciliation. Owner earnings fell about 7% in 2025 ($0.44 vs $0.50 per share, down 12% after a 7% larger share count). Our base case assumes 0% in year one, above that trailing figure, because the April 2025 fee reset was fully lapped by April 1, 2026 and the first two quarters of 2026 (net income of about $11M each, revenue up 13% in the second quarter) annualize to roughly the same earnings level as 2025. We give no credit for growth after that: the clinic count slipped from 241 to 237 during 2025, and new clinics, new markets and acquisitions are not a proven repeatable process here. Cases. Every case discounts the business's cash flow at 6%, then subtracts borrowings and adds cash the business does not need. The company holds $184M of cash (June 2026) against about $43M of bank borrowings (mostly at low Japanese rates, which we did not adjust for). We treat $50M of cash as needed to run the business and count the rest. - Base: $45M a year, flat, for ten years, then fading 10% a year. The 25-year brand, 6.6 million customer visits in 2025 (up from 3.0M in 2021) and a 72% repeat rate support persistence; nothing supports growth. Business worth about $472M ($4.59 a share); net cash of about $91M ($0.89 a share). Value about $5.47 per share. - Bear: a second fee reset of similar size to April 2025, plus the extra annualization of the first one (Q1 2025 was still at old rates), takes cash flow to $30M, then it slips 5% a year and fades 15% a year after year ten. We also assume $25M of the roughly $43M spent on acquisitions and equity stakes in 2025 earns nothing. Business worth about $224M ($2.18 a share), net cash about $66M ($0.64 a share). Value about $2.82 per share. Borrowings are small relative to cash flow in every case, so refinancing is not the issue; control by related parties is. - Bull: revenue keeps recovering as in the second quarter of 2026 and the acquired Singapore and career-services businesses contribute for full years, lifting cash flow to $52M, flat for ten years, then fading 7% a year. Business worth about $590M ($5.73 a share), net cash about $91M ($0.89). Value about $6.62 per share. Treatment of intangibles. Acquired intangibles rose to $47.7M and goodwill to $15.4M in 2025. Amortization is added back as a non-cash charge; the decay is carried in the flat-to-fading path rather than by cutting today's earnings. What could make this wrong. The main risk is that the controlling shareholder, who owns both sides of the fee arrangement, resets fees again; the bear case is built on that. Japanese cosmetic-clinic regulation, yen moves (revenue is mostly in yen and 2025 was helped by yen appreciation) and dependence on three medical corporations are other named risks. Upside beyond the bull case would require clinic-count growth or higher fees, which the filings do not show. We could not verify how much of the yen strength or the 2026 rebound is durable.